[
  {
    "ts": "2025-10-11T18:06:52+00:00",
    "headline": "Why Analysts See AbbVie’s Story Shifting After Strategic Wins and Growth Upgrades",
    "summary": "AbbVie shares have seen their consensus analyst price target rise from $227.22 to $232.78 per share, reflecting growing optimism from Wall Street. This shift follows positive business developments, including key litigation wins, robust sales results, and updates to growth guidance projections. Stay tuned to discover how investors can track these evolving expectations and position themselves for future changes in AbbVie's story. What Wall Street Has Been Saying Recent analyst commentary on...",
    "url": "https://finance.yahoo.com/news/why-analysts-see-abbvie-story-180652025.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "bd9a86a1-7f47-3c96-b5ed-4f00456f3b79",
      "content": {
        "id": "bd9a86a1-7f47-3c96-b5ed-4f00456f3b79",
        "contentType": "STORY",
        "title": "Why Analysts See AbbVie’s Story Shifting After Strategic Wins and Growth Upgrades",
        "description": "",
        "summary": "AbbVie shares have seen their consensus analyst price target rise from $227.22 to $232.78 per share, reflecting growing optimism from Wall Street. This shift follows positive business developments, including key litigation wins, robust sales results, and updates to growth guidance projections. Stay tuned to discover how investors can track these evolving expectations and position themselves for future changes in AbbVie's story. What Wall Street Has Been Saying Recent analyst commentary on...",
        "pubDate": "2025-10-11T18:06:52Z",
        "displayTime": "2025-10-11T18:06:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cbaG7tZ9A8mqrilci3AeIQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1OA9tdPdimVe1Dv1fa4MAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-abbvie-story-180652025.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-abbvie-story-180652025.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]